Heart failure study unlocks metabolic secrets of common drug
NCT ID NCT05885607
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how SGLT2 inhibitors, a type of diabetes drug also used for heart failure, affect the body's metabolism. About 40 adults with mild to moderate heart failure will have blood tests, walking tests, and calf MRIs before and after starting the medication. The goal is to understand early changes in energy use and muscle function, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study will be performed in approximately 40 outpatient participants with symptomatic heart failure (HF) who are being started on SGLT2i treatment by their provider.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Clinically diagnosed HF documented in the patient's medical record * NYHA Class II-III functional status, according to the most recent clinical evaluation * Availability of an echocardiogram or cardiac MRI within the prior year * Stable HF medical therapy (no change in beta-blocker, ACE/ARB, ARNI or MRA for at least 4 weeks prior to screening) with the exception of diuretics * Planned initiation of on-label SGLT2i therapy Exclusion Criteria: * Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or previous intolerance to an SGLT2 inhibitor * Subject inability/unwillingness to perform a six-minute walk test * Acute coronary syndrome or unstable angina within the past month * Previous cardiac transplantation or implantation of a ventricular assist device * Any condition that will interfere with the completion of the study. This may include comorbid conditions or logistical factors that may impede successful completion of the protocol (e.g. inability to travel for follow-up visits) Absolute Exclusions for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing): * ANY intracranial implants of any type other than dental fillings * ANY non-removable piercings, jewelry, or medicinal patch * ANY personal history of intraocular injury or fragment in or around the orbit that cannot be cleared through radiologic examination * ANY personal history of bullet, shrapnel, or stabbing wounds that cannot be cleared through radiologic evaluation. * ANY non-removable life assist device, pump, or prosthetic Possible Exclusions\*\* for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing): * An intra-luminal implant, filter, stent, or valve replacement * A vascular clip or clamp * A surgically placed clip, clamp or band on visceral organs * A cardiac pacemaker or implanted cardiac defibrillator (ICD)##
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?